| 1 |
Ferlay J,Bray F,Pisani P,et al.GLOBOCAN 2000:cancerincidence,mortality and prevalence worldwide. version 1.0. IARC, CancerBase No.5.Lyon:IARC 2001.
|
| 2 |
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.Ann Surg,1999,230(3):309-321.
|
| 3 |
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases.J Clin Oncol,1997,15(3):938-946.
|
| 4 |
Scheele J,Altendorf-Hofmann A.Resection of colorectal liver metastases. Langenbecks Arch Surg,1999,384(4):313-327.
|
| 5 |
Goslin R,Steele G Jr,Zamcheck N,et al.Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum.Dis Colon Rectum,1982,25(8):749-754.
|
| 6 |
Wagner JS,Adson MA,Van Heerden JA,et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment.Ann Surg,1984,199(5):502-508.
|
| 7 |
Simmonds PC. Palliative chemotherapy for advanced colorectal cancer:systematic review and meta-analysis.Colorectal Cancer Collaborative Group.BMJ,2000 321(7260):531-535.
|
| 8 |
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol, 1992, 10(6):896-903.
|
| 9 |
Kelly H,Goldberg RM.Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol, 2005, 23(20):4553-4560.
|
| 10 |
ournigand C,André T,Achille E,et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol,2004,22(2):229-237.
|
| 11 |
Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemo therapy in the treatment of multiple colorectal metastases to the liver.Br J Surg,2003,90(8):963-969.
|
| 12 |
Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.J Clin Oncol,2005,23(9):2038-2048.
|
| 13 |
Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.Ann Oncol,2005,16(8):1311-1319.
|
| 14 |
Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil,and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.J Clin Oncol,2005,23:9243-9249.
|
| 15 |
Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.Ann Surg Oncol,2006,13(1):58-65.
|
| 16 |
Pozzo C, BassoM, CassanoA, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.Ann Oncol,2004,15(6):933-939.
|
| 17 |
Giacchetti S,Itzhaki M,Gruia G,et al.Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.Ann Oncol,1999,10(6):663-669.
|
| 18 |
Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinot ecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998, 352(9138):1407-1412.
|
| 19 |
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. irinotecan study group. N Engl J Med,2000,343(13):905-914.
|
| 20 |
Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy,Ann Surg,1996,224(4):509-520.
|
| 21 |
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Ann Surg,2004,240(4):644-657.
|
| 22 |
Borner M,Mingrone W,Koeberle D,et al.The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in firstline treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol,2006 ASCO Annual Meeting Proceedings Part I; 24:Abstract 3551.
|
| 23 |
Diaaz Rubio E,Tabernero J,van Cutsem E,et al.Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA)(FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. Journal of Clinical Oncology 2005 ASCO Annual Meeting Proceedings Part I;23:Abstract 3535.
|
| 24 |
Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.Ann Oncol,2006,17(3):450-456.
|
| 25 |
Van Cutsem E,Lang I,D'Haens G,et al.KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer(mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience.J Clin Oncol,2008,26(suppl):abstract 2.
|
| 26 |
Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer(mCRC) with FOLFOX with or without cetuximab: The OPUS experience.J Clin Oncol,2008,26(suppl):abstract 4000.
|
| 27 |
Adam R,Aloia T,Lévi F,et al.Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol, 2007, 25(29): 4593-4602.
|
| 28 |
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, luorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med, 2004,350(23):2335-2342.
|
| 29 |
Kopetz S, Abbruzzese JL, Eng C, et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan(FOL FIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer(mCRC). Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I;24:Abstract 3579.
|
| 30 |
Rothenberg ML,Cox JV, Butts C, et al. Capecitabine plus oxaliplatin(XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol, 2008, 19(10):1720-1726.
|
| 31 |
Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome.J Gastrointest Surg,2007,11(7):860-868.
|
| 32 |
Benoist S,Brouquet A,Penna C,et al.Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol,2006,24(24):3939-3945.
|